

## TOPICAL REVIEW

## Chronic vitamin C deficiency increases the risk of cardiovascular diseases\*

Ginter E

Public Health Authority of the Slovak Republic, Bratislava, Slovakia. [ginter.emil@mail.t-com.sk](mailto:ginter.emil@mail.t-com.sk)

### Abstract

The studies on experimental animals (guinea pigs, monkeys, fish) have confirmed the important role of ascorbic acid deficiency in the development of hypercholesterolemia and atherosclerosis, but the clinical experience is not quite uniform. Metaanalyses of randomized controlled trials performed on subjects without established vitamin C-deficiency conclude that the evidence of the presence or absence of benefits derived from the ability of ascorbic acid to prevent cardiovascular diseases is not sufficient. This review is an outline of numerous clinical, epidemiological and prospective studies that have found a positive role of vitamin C in the prevention of atherosclerosis. If we admit the possibility that vitamin C deficiency is a significant risk factor of atherogenesis, due to ethical reasons it is impossible to perform long-term controlled trials on subjects with proved vitamin C deficiency, to recommend them not to change their nutrition and lifestyle, and to administer placebo to the control group. Therefore the proof of atherogenic effect of chronic vitamin C deficiency is limited to indirect evidence only. In this review many new data on the positive effects of ascorbic acid on human cardiovascular system are summarized and the mechanisms of its protective influence on blood vessels are discussed (*Fig.5, Ref. 45*). Full Text (Free, PDF) [www.bmj.sk](http://www.bmj.sk).

**Key words:** vitamin C, atherosclerosis, hypercholesterolemia, lipoproteins LDL-HDL, epidemiology.

After experimental studies on vitamin C deficiency as a risk factor of atherosclerosis had been published in the second half of last century (1–4) and after Linus Pauling, double Nobel prize winner (5) had accepted these opinions, the interest in use of vitamin C in cardiovascular diseases prevention has spread significantly. Virtually, all of the studies on experimental animals have confirmed earlier findings, but the clinical experience is not quite uniform (6). The objective of this communication is to outline recent studies conducted mainly on various human populations and published after the year 1990.

### Vitamin C and cardiovascular diseases in humans

Numerous data obtained on a large number of people show lower total and cardiovascular mortality in subjects well-supplied with vitamin C. A large international team has joined 9 main studies on the influence of food antioxidants on occurrence of cardiovascular diseases and deaths on a group of 293,172 people (!). They found out that the people who had consumed preparations containing vitamin C had the risk of a cardiovascu-

lar event lowered by 27 % (7). These data are in accordance with many other authors' data on positive influence of vitamin C in prevention of cardiovascular diseases (8–16).

American authors (17) who specified the levels of various vitamins in blood in 1214 people at the age of above 75 years and followed them for 4.4 years, found a close indirect relationship between the level of vitamins and mortality (total and cardiovascular) in the case of vitamin C only (Fig. 1). People with vitamin C deficiency had double mortality in comparison with people well-supplied with ascorbate. They conclude that the level of vitamin C in blood predicts mortality of elder people very well.

---

Public Health Authority of the Slovak Republic, Bratislava, Slovakia

**Address for correspondence:** E. Ginter, RND, DSc, Public Health Authority of the Slovak Republic, Racianska 17, SK-831 02 Bratislava 3, Slovakia.

Phone: +421.2.44253993

\*The author of this review was by B. Sardi (USA) declared as the world's leading vitamin C researcher. [www.knowledgeofhealth.com](http://www.knowledgeofhealth.com).

### Total mortality and blood vitamin C




Fig. 1. Decrease in total mortality in old persons with increasing quintile of vitamin C blood concentration. According to Fletcher et al (17).

### Cardiovascular mortality and blood vitamin C




Fig. 2. Decrease in the relative risk of cardiovascular mortality with increasing quintile of vitamin C levels in the blood. According to Khaw et al (16).

In Great Britain the relationship between the level of ascorbic acid in plasma and cardiovascular mortality in 19,496 people at the age of 45–79 years in a prospective four-year study was followed (16). The risk of cardiovascular mortality was more than doubled in people with vitamin C deficiency in comparison with people well-supplied with ascorbic acid (Fig. 2). The relationship between mortality and the level of ascorbic acid in plasma was continuous. The increase in the ascorbate level by 20  $\mu\text{mol/l}$ , which is equivalent to daily consumption of about 50 g of vegetables or fruit, caused a decrease in total mortality by 20 %. The authors conclude that a small increase in vegetable or fruit consumption is connected with increased prevention of cardiovascular diseases. In a Finnish prospective study conducted on 1605 men at the age of 42–60 years, their health condition was monitored for 5 years after the analysis of vitamin C content in plasma and composition of their diet (12). In people with vitamin C deficiency (the level in plasma below 11.4  $\mu\text{mol/l}$ , i.e. 0.2 mg %)

### Risk of myocardium infarction and blood vitamin C In Finland males




Fig. 3. Significant increase in the risk of myocardial infarction in men with biochemically proved vitamin C-deficiency. According to prospective study of Nyssönen et al (12).

the risk of a heart attack was increased severely (Fig. 3). After the correction according to age and smoking this number got lower but it was still significantly higher than in all of the other groups better supplied with vitamin C.

The protective effect of vitamin C or fruit on cardiovascular system has been described as well in a number of other English (18), American (19), Finnish (20), Chinese (21), Japanese (22) and Austrian (23) reports. Entering the query “vitamin C – cardiovascular disease” in the GOOGLE gave 834 responses. The well-known protective effect of the Mediterranean diet is also put down to the high content of vitamin C besides the high content of mono-unsaturated fatty acids and low content of saturated fats (24).

The results of studies on the protective effect of vitamin C in smokers published quite recently are interesting. Smoking is a well known risk factor of atherogenesis. South-Korean authors (25) found out that high intake of vitamin C was connected with a lower risk of non-fatal heart attacks in strong smokers. Vascular endothelial growth factor (VEGF) plays an important role in atherogenesis. This factor stimulates monocyte migration, but not in smokers. Administration of vitamin C normalized the monocyte reaction (26). Administration of vitamin C lowered the oxidation stress when caused by smoking (27). These findings are important because the occurrence of vitamin C deficiency in smokers has been known for a long time.

It is necessary to stress out that there are also some studies that report a slight or non-significant effect of vitamin C on plasmatic lipids or atherogenesis in humans (28–30).

### Mechanism of protective activity of vitamin C

#### 1. Effect on cholesterol metabolism

Besides smoking, hypercholesterolemia is an important risk factor of cardiovascular diseases. Chronic vitamin C deficiency lowers cholesterol transformation into its main catabolic product -cholic acids due to lowered activity of the key enzyme of

cholesterol catabolism - 7-alpha-cholesterol hydroxylase (3, 4). Vitamin C inhibits the key enzyme of endogenous cholesterol synthesis in human leukocytes (31). Therefore it is understandable that in case of vitamin C deficiency cholesterol accumulates in the body, and vice versa, after administration of ascorbic acid the cholesterol concentration decreases. Ascorbate deficiency manifests not only by the increase in the cholesterol level in blood, its accumulation in arteries (4), but also by increased formation of cholesterol bile stones in humans (32).

### 2. Lowering of blood pressure

It is well-known that besides smoking and hypercholesterolemia, hypertension is another serious risk factor of atherogenesis. In five studies it has been found out that people well-supplied with vitamin C are less endangered by hypertension than those with deficient supply with ascorbic acid. Some other authors did not observe such an effect.

### 3. Antioxidant effects of ascorbic acid

It has been known for a long time that the oxidized form of the main cholesterol carrier in plasma – LDL (low-density lipoproteins) is more dangerous in respect of atheroma development than intact LDL. Owing to its strong antioxidant effects, the ascorbic acid protects LDL from peroxidation, and it keeps LDL ability to bind to LDL-receptors (34–36). Orange juice has the same effect as the ascorbic acid (37). Owing to its antioxidant effects, carotid atherosclerosis is less pronounced in men with high blood levels of vitamins C and E (38). By means of the same mechanism, ascorbic acid has a protective effect also in the development of Alzheimer disease (39).

### 4. Effect of vitamin C on haemostatic factors

In cardiovascular disease the development of thrombosis plays an important role. It has been found out that deficiency in vitamin C increases the blood coagulation, and that administration of ascorbic acid normalizes the situation (40, 41). Vitamin C has a beneficial effect on endothelial function in children with familial hyperlipemia.

## Vitamin C deficiency and epidemiology of cardiovascular mortality

The extremely high cardiovascular mortality in Western Europe, especially in Finland in the 1960's led to a series of remedial measures, which were especially the substitution of butter for vegetable fats, better monitoring and therapy of hypertension, decrease in smoking and increase in vegetable and fruit consumption. Under the thumb of studies about the protective effects of vitamin C, the consumption of natural and synthetic ascorbic acids has increased. In the whole of Western Europe, and especially in Finland and European Union, premature cardiovascular mortality fell rapidly; this phenomenon moved also to Central Europe after the fall of totalitarian regimes and resulted in an increase in fruit, juices and vegetable consumption (42) (Fig. 4). It is possible that the decrease in chronic vitamin C

### Male premature cardiovascular mortality (0-64 years) in EU, Slovakia and Czech Republic




Fig. 4. Decrease in the standardized premature male cardiovascular mortality (age 0–64 years) in the European Union, Slovak and Czech Republics. According to WHO (42).

### Male premature cardiovascular mortality (0-64 years) in Russia, Belarus and Ukraine




Fig. 5. Increase in the standardized premature male cardiovascular mortality (age 0–64 years) in the European countries formed in the territory of the former USSR. According to WHO (42).

deficiency saved millions of lives in Europe. On the other hand, the cardiovascular mortality is still growing in the countries established in the territory of the former USSR (42) (Fig. 5). It is well-known that in this area chronic vitamin C deficiency persists especially in long winter periods and that it may cause, along with other risk factors (e.g. alcoholism, smoking and psychological factors) extremely high cardiovascular mortality.

## Conclusion

The sceptical views on the usefulness of vitamin C in the prevention of cardiovascular diseases object that even in the face of many positive reports the evidence of vitamin C deficiency is

not direct (43–45). These authors assert that the final proof could be given by double-blinded study in which vitamin C or placebo would be administered to people with vitamin C deficiency, and in which the effect (total and cardiovascular mortality, non-fatal cardiovascular events, HDL and LDL lipoproteins levels, blood pressure etc.) would be followed for at least 5 years. As an exemplar they mention perfect studies conducted with statins (4S, WOSCOP and CARE). Disregarding the fact that these are financially extremely demanding projects, such a project would be infeasible for working and ethical reasons. It would be necessary to select biochemically at least 5,000 people by analyzing their levels of ascorbic acid in blood. Such a selection could be carried out in Russia, but hardly in the European Union or USA. If we admit the probable possibility that vitamin C deficiency is a significant risk factor of atherogenesis, it is not possible to leave these people with a biochemically proved vitamin C deficiency for 5 years, to recommend them not to change their diet and to administer them placebo. Therefore the proof of atherogenic effect of chronic vitamin C deficiency is limited to indirect evidence only.

## References

1. **Willis GC.** The reversibility of atherosclerosis. *Canad Med Ass J* 1957; 77: 106–109.
2. **Fujinami T, Okado K, Senda K et al.** Experimental atherosclerosis with ascorbic acid deficiency. *Jap Circul J* 1971; 35: 1559–1565.
3. **Ginter E.** Cholesterol: vitamin C controls its transformation to bile acids. *Science* 1973; 179: 702–704.
4. **Ginter E.** Marginal vitamin C deficiency, lipid metab, and atherogenesis. *Adv Lipid Res* 1978; 16: 167–220.
5. **Rath M, Pauling L.** Hypothesis: Lipoprotein(a) is a surrogate for ascorbate. *Proc Natl Acad Sci* 1990; 87: 6204–6207.
6. **Huang HY, Caballero B, Chang S et al.** The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults. *Ann Intern Med* 2006; 145: 372–385.
7. **Knekt P, Ritz J, Pereira MA et al.** Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. *Amer J Clin Nutr* 2004; 80: 1508–1520.
8. **Enstrom JE, Kanim LE, Klein MA.** Vitamin C intake and mortality among a sample of the United States population. *Epidemiology* 1992; 3: 194–202.
9. **Sahyoun NR, Jacques PF, Russell RM.** Carotenoids, vitamins C and E, and mortality in an elderly population. *Amer J Epidemiol* 1996; 144: 501–511.
10. **Osganian SK, Stampfer MJ, Rimm E et al.** Vitamin C and risk of coronary heart disease in women. *J Amer Coll Cardiol* 2003; 42: 246–252.
11. **Pandey DK, Shekelle R, Selwyn BJ et al.** Dietary vitamin C and beta-carotene and risk of death in middle-aged men. The Western Electric Study. *Amer J Epidemiol* 1995; 142: 1269–1278.
12. **Nyyssönen K, Parviainen MT, Salonen R et al.** Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. *Brit Med J* 1997; 314: 634–638.
13. **Tunstall-Pedoe H, Woodward M, Tavendale R et al.** Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. *Brit Med J* 1997; 315: 722–729.
14. **Simon JA, Hudes ES, Tice JA.** Relation of serum ascorbic acid to mortality among US adults. *J Amer Coll Nutr* 2001; 20: 255–263.
15. **Todd S, Woodward M, Tunstall-Pedoe H et al.** Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes mortality: results from the Scottish Heart Health Study. *Amer J Epidemiol* 1999; 150: 1073–1080.
16. **Khaw KT, Bingham S, Welch A et al.** Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. *European Prospective Investigation into Cancer and Nutrition. Lancet* 2001; 357: 657–663.
17. **Fletcher AE, Breeze E, Shetty PS.** Antioxidant vitamins and mortality in older persons. *Amer J Clin Nutr* 2003; 78: 999–1010.
18. **Gale CR, Martyn CN, Winter PD et al.** Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. *Brit Med J* 1995; 310: 1563–1566.
19. **Joshiyura KJ, Ascherio A, Manson JE et al.** Fruit and Vegetable Intake in Relation to Risk of Ischemic Stroke. *J Amer Med Ass* 1999; 282: 1233–1239.
20. **Salonen RM, Nyyssonen K, Kaikkonen J et al.** Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. *Circulation* 2003;107: 947–953.
21. **Ling L, Zhao SP, Gao M et al.** Vitamin C preserves endothelial function in patients with coronary heart disease after a high-fat meal. *Clin Cardiol* 2002; 25: 219–224.
22. **Okamoto K.** Vitamin C intake and apolipoproteins in a healthy elderly Japanese population. *Prev Med* 2002; 34: 364–369.
23. **Deicher R, Ziai F, Bieglmayer C et al.** Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. *J Amer Soc Nephrol* 2005; 16c: 1011–1018.
24. **Kok FJ, Kromhout D.** Atherosclerosis — epidemiological studies on the health effects of a Mediterranean diet. *Europ J Nutr* 2004; 43 (Suppl 1): I/2–5.
25. **Nam CM, Oh KW, Lee KH et al.** Vitamin C intake and risk of ischemic heart disease in a population with a high prevalence of smoking. *J Amer Coll Nutr* 2003; 22: 372–378.
26. **Stadler N, Eggermann J, Voo S et al.** Smoking-induced monocyte dysfunction is reversed by vitamin C supplementation in vivo. *Arterioscler Thromb Vasc Biol* 2007; 27: 120–126.
27. **Dietrich M, Block G, Benowitz NL et al.** Vitamin C supplementation decreases oxidative stress biomarker f2-isoprostanes in plasma of nonsmokers exposed to environmental tobacco smoke. *Nutr Cancer* 2003; 45: 176–184.
28. **Heart Protection Study Collaborative Group.** MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360: 23–33.
29. **Brown BG, Zhao XQ, Chait A et al.** Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *New Engl J Med* 2001; 345: 1583–1592.

30. Daviglus ML, Orenca AJ, Dyer AR et al. Dietary vitamin C, beta-carotene and 30-year risk of stroke: results from the Western Electric Study. *Neuroepidemiology* 1997; 16: 69—77.
31. Harwood HJ, Greene YJ, Stacpole PW. Inhibition of human leukocyte 3-hydroxy-3-methyl coenzyme A reductase activity by ascorbic acid. *J Biol Chem* 1986; 261: 7127—7135.
32. Simon JA, Hudes ES. Serum ascorbic acid and gallbladder disease prevalence among US adults. *Arch Intern Med* 2000; 160: 931—936.
33. Trout DL. Vitamin C and cardiovascular risk factors. *Amer J Clin Nutr* 1991; 53 (Suppl 1): 322S—325S.
34. Sakuma N, Yoshikawa M, Hibino A et al. Ascorbic acid protects against peroxidative modification of low-density lipoprotein, maintaining its recognition by LDL receptors. *J Nutr Sci Vitaminol (Tokyo)* 2001; 47: 28—31.
35. Shidfar F, Keshavarz A, Jallali M et al. Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients. *Int J Vitam Nutr Res* 2003; 73: 163—170.
36. Evans M, Anderson RA, Smith JC et al. Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. *Europ J Clin Invest* 2003; 33: 231—238.
37. Johnston CS, Dancho CL, Strong GM. Orange juice ingestion and supplemental vitamin C are equally effective at reducing plasma lipid peroxidation in healthy adult women. *J Amer Coll Nutr* 2003; 22: 519—523.
38. Gale CR, Ashurst HE, Powers HJ et al. Antioxidant vitamin status and carotid atherosclerosis in the elderly. *Amer J Clin Nutr* 2001; 74: 402—408.
39. Engelhart MJ, Geerlings MI, Ruitenber A et al. Dietary intake of antioxidants and risk of Alzheimer disease. *J Amer Med Ass* 2002; 287: 3223—3229.
40. Tofler GH, Stec JJ, Stubbe I et al. The effect of vitamin C supplementation on coagulability and lipid levels in healthy male subjects. *Thromb Res* 2000; 100: 35—41.
41. Khaw KT, Woodhouse P. Interrelation of vitamin C, infection, haemostatic factors, and cardiovascular disease. *Brit Med J* 1995; 310: 1559—1563.
42. European Health for All Database. WHO Regional Office for Europe, Copenhagen, updated January 2007.
43. Bleys J, Miller ER 3rd, Pastor-Barriuso R et al. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. *Amer J Clin Nutr* 2006; 84: 880—887.
44. Tahir M, Foley B, Pate G et al. Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial. *Amer Heart J* 2005; 150: 302—306.
45. Arad Y, Spadaro LA, Roth M et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. *J Amer Coll Cardiol* 2005; 46: 166—172.

Received

Accepted September 14, 2007.